# Robin Bellas

> Robin Bellas is a Series A investor at Morgenthaler Ventures backing Medical. See 8 investments, check sizes, portfolio and contact details. Updated Oct 2026.

- Type: Angel Investor
- Fund: [Morgenthaler Ventures](https://shizune.co/investors/profile/morgenthaler-ventures)
- Location: Palo Alto, United States
- Total investments: 8
- Last investment: Apr 2014
- Lead investor: 25%
- Last updated: Oct 2026
- LinkedIn: https://www.linkedin.com/in/robinbellas

Robin Bellas is a Series A investor at Morgenthaler Ventures in Palo Alto focused on Medical and Health Care. Robin Bellas - Partener @ Lightstone Ventures

## Contacts

5 contacts available for Robin Bellas: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/robin-bellas?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 4 | 50% |
| Health Care | 4 | 50% |
| Biotechnology | 2 | 25% |
| Incubators | 1 | 13% |
| Medical Device | 1 | 13% |

6 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 25% |
| Series B | 2 | 25% |
| Series C | 2 | 25% |
| Funding Round | 2 | 25% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| ForSight VISION5 | ForSight VISION5 was founded in 2010 as the fifth company created by the ophthalmic product incubator, ForSight Labs. ForSight VISION5 is developing non-invasive products that replace eye drops and provide sustained therapy for major eye diseases including glaucoma, dry eye, and allergy. The company is currently in its second Phase 2 clinical studyfor its lead product, the Helios insert. | $15M | Series C | Apr 16, 2014 | http://forsightvision5.com |
| ForSight Labs | ForSight Labs is focused on developing and applying solutions to improve the sight, care, and quality of life of visually impaired patients. Our environment is creative and collaborative; a place where entrepreneurs and investors work together to drive innovative technologies through concept, development, and ultimately commercialization inhigh-impact eye care companies (ForSight VISION companies).Each day millions of people rely on their vision and suffer when it is lost. There are few disabilities as impactful to quality of life as the loss of vision. The number of people with impaired vision in the US, including blindness, is expected to more than double over the next three decades. Recent estimates of the cost of vision loss in the US exceed $50 billion dollars annually. ForSight Labs brings together highly motivated and capable team members, clinicians and investors focused on starting and sustaining efforts to deliver innovative solutions to the ophthalmic community and the patients it serves. |  | Series C | Apr 16, 2014 | http://www.forsightlabs.com |
| ForSight Labs | ForSight Labs is focused on developing and applying solutions to improve the sight, care, and quality of life of visually impaired patients. Our environment is creative and collaborative; a place where entrepreneurs and investors work together to drive innovative technologies through concept, development, and ultimately commercialization inhigh-impact eye care companies (ForSight VISION companies).Each day millions of people rely on their vision and suffer when it is lost. There are few disabilities as impactful to quality of life as the loss of vision. The number of people with impaired vision in the US, including blindness, is expected to more than double over the next three decades. Recent estimates of the cost of vision loss in the US exceed $50 billion dollars annually. ForSight Labs brings together highly motivated and capable team members, clinicians and investors focused on starting and sustaining efforts to deliver innovative solutions to the ophthalmic community and the patients it serves. | $9.3M | Series B | Jun 17, 2013 | http://www.forsightlabs.com |
| Nexis Vision | Nexis Vision develops ophthalmic solutions. The company is developing ocular surface technology for ophthalmic devices. The company was founded in 2007 and is based in Menlo Park, California. Nexis Vision, Inc. operates as a subsidiary of ForSight Labs, LLC. |  | Series B | Jun 18, 2009 |  |
| Nexis Vision | Nexis Vision develops ophthalmic solutions. The company is developing ocular surface technology for ophthalmic devices. The company was founded in 2007 and is based in Menlo Park, California. Nexis Vision, Inc. operates as a subsidiary of ForSight Labs, LLC. |  | Series A | Jan 07, 2008 |  |
| ForSight Labs | ForSight Labs is focused on developing and applying solutions to improve the sight, care, and quality of life of visually impaired patients. Our environment is creative and collaborative; a place where entrepreneurs and investors work together to drive innovative technologies through concept, development, and ultimately commercialization inhigh-impact eye care companies (ForSight VISION companies).Each day millions of people rely on their vision and suffer when it is lost. There are few disabilities as impactful to quality of life as the loss of vision. The number of people with impaired vision in the US, including blindness, is expected to more than double over the next three decades. Recent estimates of the cost of vision loss in the US exceed $50 billion dollars annually. ForSight Labs brings together highly motivated and capable team members, clinicians and investors focused on starting and sustaining efforts to deliver innovative solutions to the ophthalmic community and the patients it serves. |  | Series A | Apr 03, 2007 | http://www.forsightlabs.com |
| ForSight Labs | ForSight Labs is focused on developing and applying solutions to improve the sight, care, and quality of life of visually impaired patients. Our environment is creative and collaborative; a place where entrepreneurs and investors work together to drive innovative technologies through concept, development, and ultimately commercialization inhigh-impact eye care companies (ForSight VISION companies).Each day millions of people rely on their vision and suffer when it is lost. There are few disabilities as impactful to quality of life as the loss of vision. The number of people with impaired vision in the US, including blindness, is expected to more than double over the next three decades. Recent estimates of the cost of vision loss in the US exceed $50 billion dollars annually. ForSight Labs brings together highly motivated and capable team members, clinicians and investors focused on starting and sustaining efforts to deliver innovative solutions to the ophthalmic community and the patients it serves. |  |  | Jan 06, 2006 | http://www.forsightlabs.com |
| Third Millennium Healthcare Systems | Founded in January,1999 to specifically address the Internet-based needs of the healthcare industry, Third Millennium Healthcare Systems’ solutions are focused on:Offering transaction-based services with "per-use" pricing- Assuring cost-effective, convenient setup- Improving financial performance- Minimizing capitalexpenditure and installation requirementsTheir team, employees and management alike, makes all the difference. Third Millennium Healthcare Systems’ employees are experienced in Internet applications, software design and development, business office functions, consulting, accounts receivables management, business office outsourcing, claims processing and superior customer service and support. |  |  | Aug 08, 2000 | http://www.3mhs.com/ |

8 of 8 investments shown.

## Co-investors
- [Split Rock Partners](https://shizune.co/investors/profile/split-rock-partners) — VC Fund, 4 deals together
- [Versant Ventures](https://shizune.co/investors/profile/versant-ventures) — VC Fund, 3 deals together
- [Delphi Ventures](https://shizune.co/investors/profile/delphi-ventures) — VC Fund, 2 deals together
- [H.I.G. BioHealth Partners](https://shizune.co/investors/profile/h-i-g-biohealth-partners) — VC Fund, 2 deals together
- [Technology Partners](https://shizune.co/investors/profile/technology-partners) — VC Fund, 1 deal together

## About Morgenthaler Ventures

VC Fund · Menlo Park, United States

Morgenthaler Ventures has been in the venture capital business for more than 45 years, steadily investing through every market cycle. Select past and present portfolio companies in the IT space include: Evernote, Lending Club, Siri, MuleSoft, Practice Fusion, Adara Media, Check, Doximity, PeopleMatter, Socrata, NuoDB, Jaspersoft, VoltageSecurity, Rhythm NewMedia, Nominum, Wize Commerce (NexTag) and back in the day, Apple.

5 contacts available at Morgenthaler Ventures.

| Name | Title | Profile |
| --- | --- | --- |
| Bob Pavey | Partner | https://shizune.co/investors/profile/bob-pavey |
| Gary Morgenthaler | Partner | https://shizune.co/investors/profile/gary-morgenthaler |
| Hank Plain | Partner | https://shizune.co/investors/profile/hank-plain |
| Ralph Christoffersen | Partner | https://shizune.co/investors/profile/ralph-e-christoffersen |
| Bridget Odorcic | Operations & Fund Compliance Manager | https://shizune.co/investors/profile/bridget-odorcic |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Robin Bellas invest in?

Robin Bellas invests primarily in Medical, Health Care and Biotechnology startups, most often at Series A and Series B stage. Most of the 8 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Robin Bellas?

Public channels for Robin Bellas include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Robin Bellas last invest?

The most recent investment recorded for Robin Bellas closed in Apr 2014. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co